Drug safety of rosiglitazone and pioglitazone in France: A study using the French PharmacoVigilance database

BMC Clinical Pharmacology

Volumn 11, Issue , 2011, Pages

  Berthet, Stephanie ^a   Olivier, Pascale ^a,b   Montastruc, Jean Louis ^a,b   Lapeyre Mestre, Maryse ^a,b  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b Hopitaux de Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BENFLUOREX; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFANILAMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

AGED; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; DATA BASE; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; EDEMA; ENDOCRINE DISEASE; ERYTHROCYTE DISORDER; FEMALE; FETUS DISEASE; FRANCE; GENDER; HEARING DISORDER; HEART FAILURE; HEART INFARCTION; HEPATITIS; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; RESPIRATORY SYSTEM; RETICULOENDOTHELIAL SYSTEM; RISK ASSESSMENT; SIDE EFFECT; SKIN DISEASE; URINARY TRACT DISEASE; VASCULAR DISEASE; VESTIBULAR DISORDER; VISUAL DISORDER; ADULT; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; MIDDLE AGED; TOXIC HEPATITIS;

ADULT; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG-INDUCED LIVER INJURY; EDEMA; FEMALE; FRANCE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THIAZOLIDINEDIONES;

EID: 79956280966     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-11-5     Document Type: Article

References (32)

1. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice. Expert Opin Drug Saf 2009, 8:15-32. 10.1517/14740330802597821, 19236215.
2. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect?. Drug Saf 2001, 24:873-88. 10.2165/00002018-200124120-00002, 11735645.
3. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002, 22:924-9. 10.1592/phco.22.11.924.33626, 12126225.
4. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26:2983-9. 10.2337/diacare.26.11.2983, 14578227.
5. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequaly controlled insulin-treated type2 diabetes. Diabetes Care 2001, 24::1226-32. 10.2337/diacare.24.7.1226, 11423507.
6. European Medicines Agency European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Anti-diabetes medication to be taken off the market. 2010, EMA/585784/2010 (accessed on May 17, 2011), European Medicines Agency., http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf
7. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-8. 10.1001/jama.2010.920, 20584880.
8. Nissen SE, Wolski K. Rosiglitazone revisited. An updated meta analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191-1201. 10.1001/archinternmed.2010.207, 20656674.
9. Thiessard F, Roux E, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Tubert-Bitter P, Begaud B. Trends in spontaneous adverse drug reaction reports to the French PharmacoVigilance system (1986-2001). Drug Saf 2005, 28:731-740. 10.2165/00002018-200528080-00007, 16048358.
10. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356:1255-1259. 10.1016/S0140-6736(00)02799-9, 11072960.
11. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985, 40:111-118.
12. WHO collaborating Center for International Drug monitoring WHO International monitoring of adverse reactions to drugs: adverse reaction terminology Uppsala 2011, WHO collaborating Center for International Drug monitoring.
13. Lemeshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982, 115:92-106.
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-71. 10.1056/NEJMoa072761, 17517853.
15. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-95. 10.1001/jama.298.10.1189, 17848653.
16. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komadja M, McMurray JJV, . for the RECORD Study Group Rosiglitazone evaluated for cardiovascular outcomes in oral combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009, 373:2125-35. 10.1016/S0140-6736(09)60953-3, 19501900, for the RECORD Study Group.
17. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-8. 10.1001/jama.298.10.1180, 17848652.
18. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335:497. 10.1136/bmj.39314.620174.80, 1971204, 17761999.
19. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634-43. 10.1001/jama.298.22.2634, 18073359.
20. Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005, 7:161-9. 10.1111/j.1463-1326.2004.00382.x, 15715889.
21. Floyd JS, Barbehenn E, Lurie P, Wolfe SM. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf 2009, 18:1238-43. 10.1002/pds.1804, 19623674.
22. Lapeyre-Mestre M, de Castro AM, Bareille MP, Del Pozo JG, Requejo AA, Arias LM, Montastruc JL, Carvajal A. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006, 20:391-5. 10.1111/j.1472-8206.2006.00416.x, 16867024.
23. Bégaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002, 288:1588. 10.1001/jama.288.13.1588, 12350188.
24. Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. Eur J Clin Pharmacol 1997, 52:423-427. 10.1007/s002280050314, 9342576.
25. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure. A teleo-analysis. Diabetes Care 2007, 30:2148-2153. 10.2337/dc07-0141, 17536074.
26. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32-9. 2612065, 19073651.
27. Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs : a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003, 26:142-5. 10.1097/00002826-200305000-00007, 12782916.
28. Berthet S, Grolleau S, Brefel-Courbon C, Montastruc JL, Lapeyre-Mestre M. Prevalence of Diabetes in France and Drug Use: Study Based on the French PharmacoVigilance Database. Therapie 2007, 62:483-488. 10.2515/therapie:2007076, 18316014.
29. Marant C, Romon I, Fosse S, Weill A, Simon D, Eschwège E, Varroud-Vial M, Fagot-Campagna A. French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors. Diabetes Metab 2008, 34:38-45.
30. Institut de Veille Sanitaire Le diabète. Echantillon national témoin représentatif des personnes diabétiques (Entred) 2007-2010 Institut de Veille Sanitaire.
31. (accessed on May 17, 2011)., http://www.invs.sante.fr/surveillance/diabete/entred_2007_2010/index.html
32. Agence Nationale d'Accréditation et d'Evaluation en Santé Principes de dépistage du diabète de type 2. Paris : ANAES 2003, Agence Nationale d'Accréditation et d'Evaluation en Santé.